Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Glomerulosclerosis Clinical Trials

A listing of Glomerulosclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (68) clinical trials

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome. The aim of this study is to explore the effect of CCX140-B, a selective antagonist of C-C chemokine receptor type 2, on proteinuria in subjects with FSGS.


Efficacy Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease

This add-on open-label randomised controlled pragmatic trial. Sample size is calculated based on planned regression analysis. We believe an annual GFR benefit of 5 ml/min/1.73m2 is deemed significant clinically. 118 patients are therefore needed to offer a power of 70% to detect a GFR difference of 5 ml/min/1.73m2 over 48-week ...


Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

Over 1.25 million Americans have type 1 diabetes (T1D), increasing risk for early death from cardiorenal disease. The strongest risk factor for cardiovascular disease (CVD) and mortality in T1D is diabetic kidney disease (DKD). Current treatments, such as control of hyperglycemia and hypertension, are beneficial, but only partially protect against ...


Impact of Metabolic Surgery on Pancreatic Renal and Cardiovascular Health in Youth With Type 2 Diabetes

Type 2 diabetes (T2D) in youth is increasing in prevalence in parallel with the obesity epidemic. In the US, almost half of patients with renal failure have DKD, and 80% have T2D. Compared to adult-onset T2D, youth with T2D have a more aggressive phenotype with greater insulin resistance (IR), more ...


Prognostic Imaging Biomarkers for Diabetic Kidney Disease

STUDY OVERVIEW Prognostic Imaging Biomarkers for Diabetic Kidney Disease (iBEAt) is a prospective observational multi-centre collaborative cohort study, conducted in 6 European countries. It will have a first phase with a cross-sectional design (for an association study - primary objective) and a second phase with a longitudinal design (for a ...

Phase N/A

Safety Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy

LMB763 addresses fibrosis, oxidative stress, inflammation and cell death, and therefore has the potential to improve the management of diabetic kidney disease when added to the standard of care (angiotensin converting enzyme inhibitor or angiotensin receptor blocker). This non-confirmatory Phase 2 study is designed to determine the safety, tolerability, efficacy, ...


PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Recurrent FSGS is a risk factor for graft lost: Recurrence of FSGS can occur rapidly, within minutes of transplantation, and can lead to immediate onset of proteinuria and graft dysfunction. Recurrent FSGS is definitively diagnosed with a kidney biopsy. Early kidney biopsies in recurrent FSGS often demonstrate only extensive foot ...


Molecular Analysis of Diabetic Kidney Disease Biopsies

RESEARCH OBJECTIVES A. To identify differences in transcription profiles obtained from residual kidney tissue which was obtained for clinical purposes. B. To identify differences in transcription profile between patients whose loss of kidney function progresses rapidly (eGFR decline 4ml/min/year) and in whom it progresses more slowly (eGFR decline <4ml/min/year). C. ...

Phase N/A

Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function, reduce the risk of kidney failure, or reduce the risk of death due to kidney disease in participants with diabetic kidney disease (DKD).


Effects of Fenofibrate Therapy in Diabetic Nephropathy

In this single-centre, open label study, 300 adults with DN will be recruited over 3 years. Following screening and baseline metabolic evaluations, eligible subjects will be treated with fenofibrate for 30-days and re-assessed. 4.1 Study Visits and Procedures Subjects will have their written informed consent taken during Visit 1 at ...